Form 4: Director Boosts HBIO Stake Post-Split

Harvard Bioscience Director William Snider increased his direct ownership of common stock following a 10-for-1 reverse stock split.

Summary

• William Snider, a Director of Harvard Bioscience, Inc. (HBIO), reported two separate purchases of common stock.
• On March 16, 2026, Snider acquired 12,525 shares of common stock at a weighted average price of $4.99 per share, with prices ranging from $4.85 to $5.00.
• On March 17, 2026, Snider acquired an additional 8,475 shares of common stock at a weighted average price of $4.85 per share, with prices ranging from $4.80 to $4.95.
• Following these transactions, Snider's direct beneficial ownership of common stock increased to 32,000 shares.
• The reported beneficial ownership includes 11,000 restricted stock units (RSUs) that are scheduled to fully vest on December 17, 2026.
• A 10-for-1 reverse stock split of Harvard Bioscience, Inc. common stock occurred on March 13, 2026, which adjusted the previously reported 110,000 restricted stock units to 11,000 units.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as a director increasing their stake post-reverse split often indicates confidence in the company's valuation and future, though it is a single data point.

Positives

• A director's purchase of company stock, especially after a reverse stock split, typically signals confidence in the company's future prospects and valuation.
• The increased direct ownership by a key insider aligns the director's interests more closely with those of other shareholders.

Future Outlook

na

Industry Context

StockSavvy.ai notes that Form 4 filings primarily report insider transactions and do not typically provide broader industry context or competitive analysis. However, insider buying can be interpreted as a positive signal within the life sciences tools and services industry, suggesting management's belief in the company's future performance.

Related Party Transactions

• Director William Snider's purchase of common stock from the open market.

Stakeholder Impact

• Shareholders may view the director's increased stake as a positive signal of management confidence in the company's valuation and future performance, potentially influencing investor sentiment.

Next Steps

• 11,000 restricted stock units held by William Snider are scheduled to fully vest on December 17, 2026.

Key Dates

Recommendation

The director's increased stake in Harvard Bioscience following a reverse stock split suggests confidence in the company's valuation. However, this Form 4 filing alone does not provide sufficient fundamental data to warrant a 'buy' recommendation, thus a 'hold' is prudent pending further financial analysis.

Keywords

Harvard Bioscience, HBIO, Insider Trading, Form 4, Stock Purchase, Director, Reverse Stock Split, Equity Ownership, Restricted Stock Units